AMB-051 is under clinical development by AmMax Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AMB-051’s likelihood of approval (LoA) and phase transition for Tenosynovial Giant Cell Tumor took place on 12 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AMB-051 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AMB-051 is under development for the treatment of tenosynovial giant cell tumor of the knee, advanced solid tumors such as tenosynovial giant cell tumor of the knee, pancreatic cancer, colorectal cancer, non small cell lung cancer, idiopathic pulmonary fibrosis, diabetic macular edema, age related macular degeneration and polycystic kidney disease. It is administered intravenously as a concentrate for a solution. It is a fully human IgG2 monoclonal antibody against the colony-stimulating factor-1 (CSF-1 or M-CSF) receptor c-fms (CSFR1).
Quick View AMB-051 LOA Data
|Highest Development Stage|